An update on the HIV epidemic in the Netherlands

Peter Reiss
NCHIV 2013
19 November 2013
Topics

• Epidemic trends over time
  – New HIV diagnoses overall and by transmission risk group, gender, and age and stage of infection
  – Time of diagnosis: late vs. early

• Quality of care
  – The cascade of care in the Netherlands

• Combination antiretroviral treatment outcomes
  – Short- and long-term viro-/immunologic outcomes
  – Trends over time in tolerability of initial treatment
  – Virological failure and antiviral drug resistance

• HIV in pregnancy, children and adolescents

• Mortality and morbidity
  – AIDS vs. non-AIDS morbidity and mortality

• Hepatitis B and C co-infection

• Conclusions
Registered HIV diagnoses

Number per year since 1996:
Stable number **new** registered diagnoses at around 1100 per year
2011: 1047, projected 1078
2012: 947, projected 1051

Cumulative number since 1996:
20,761 HIV-1 infected individuals with a registered date of diagnosis
294 children (0-12 yr),
195 adolescents (13-17 yr),
20,272 adults (≥ 18 yr).

**17,006 currently in care**
Registered HIV diagnoses

Transmission risk groups:
- 67% MSM
- 27% heterosexuals
- 1% IDU

Age at time of diagnosis:
MSM
- \( \geq 45 \text{ yrs: } \uparrow 31\% \)
- 18-24 yrs: \( \uparrow 12\% \)
- 25-34 yrs: \( \downarrow 29\% \)

Heterosexuals
- \( \geq 45 \text{ yrs: } \uparrow 32\% \)
- 25-34 yrs: \( \downarrow 30\% \)
Late presentation at entry into care remains frequent

- 2012: 43% late entry into care
- 2012: 26% entry into care with advanced HIV disease

Late = CD4 count $< 350$ cells/mm$^3$ or AIDS
Advanced = CD4 count $< 200$ cells/mm$^3$ or AIDS
CD4 cell counts at HIV diagnosis & at start of cART

- At entry into care (median) CD4 counts:
  - 1996: 239/mm³
  - 2012: 390/mm³

- At start of cART (median) CD4 counts:
  - 1996→1997: 260 cells/mm³
  - 2012: 320 cells/mm³
Late Presentation– EU trends

Proportion

Year of presentation

Median CD4 count at presentation (cells/mm³)

LP | advanced immunodeficiency | AIDS | CD4

2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010/11

Diagnosis with recent HIV infection

MSM:

- Improvement in diagnosis at earlier stage of infection, also reflected in an increasing proportion diagnosed with recent infection
- Indicates improved testing rates amongst MSM
Topics

- **Epidemic trends over time**
  - New HIV diagnoses overall and by transmission risk group, gender, and age and stage of infection
  - Time of diagnosis: late vs. early

- **Quality of care**
  - The cascade of care in the Netherlands

- **Combination antiretroviral treatment outcomes**
  - Short- and long-term viro-/immunologic outcomes
  - Trends over time in tolerability of initial treatment
  - Virological failure and antiviral drug resistance

- **HIV in pregnancy, children and adolescents**

- **Mortality and morbidity**
  - AIDS vs. non-AIDS morbidity and mortality

- **Hepatitis B and C co-infection**

- **Conclusions**
Cascade of care: total population

Estimated number of HIV-infected
25,000
(UNAIDS)
Cascade of care: diagnosed, linked, retained, on cART

- Estimated number of HIV-infected: 25,000 (UNAIDS)
  - 73% diagnosed + linked to HIV care: 18,217
  - 93% in HIV care: 17,006
  - 87% on cART: 14,817

68%
Cascade of care: on cART and suppressed

- Estimated number of HIV-infected: 25,000 (UNAIDS)
- Diagnosed + linked to HIV care: 18,217 (73%)
- In HIV care: 17,006 (93%)
- cART: 14,817 (87%)
- HIV suppressed: 13,369 (90%)

Overall, 68% of HIV-infected individuals are on cART and suppressed.
Cascade of care: small vs large treatment centres

- Q-HIV study initial results

Ref: Esther Engelhard, 14th European AIDS Conference, October 18, 2013
Topics

- **Epidemic trends over time**
  - New HIV diagnoses overall and by transmission risk group, gender, and age and stage of infection
  - Time of diagnosis: late vs. early

- **Quality of care**
  - The cascade of care in the Netherlands

- **Combination antiretroviral treatment outcomes**
  - Short- and long-term viro-/immunologic outcomes
  - Trends over time in tolerability of initial treatment
  - Virological failure and antiviral drug resistance

- **HIV in pregnancy, children and adolescents**

- **Mortality and morbidity**
  - AIDS vs. non-AIDS morbidity and mortality

- **Hepatitis B and C co-infection**

- **Conclusions**
cART: short-term results

- 85% <100 cps RNA/ml plasma at 12 months

- Male gender
- Younger age (<30 years)
- Region of origin (Caribbean/S America, sub-Saharan Africa)

⇒ Associated with longer time to viral suppression
cART: long-term virological outcome in treatment-naïve patients

Long-term effect of continuous cART:

• 94% <50 cps RNA/ml at 12 years
cART: long-term immunological outcome in treatment-naïve patients

- Optimal immunological recovery associated with starting cART at less advanced infection and maintaining long-term suppression of viraemia
cART: reasons for modifying treatment

- First-line regimens maintained for longer
- Treatment failure has become a rare reason
- Toxicity remains main reason for change

→ Improved regimens and new drugs still necessary
cART: virological failure*

- Virological failure to first-line treatment 15% at 12 years
- Annual proportion of patients with virological failure is low
- HIV levels at time of virological failure relatively low

* HIV RNA (confirmed) >200cps/ml in treatment naïve patients after ≥24 wks on cART
cART: virological failure and drug resistance

- As of June 2013, resistance-associated mutations ever detected in 2,062 of 17,006 (12%) currently in care.

- Mutations indicative of high level resistance to at least one drug found in 1,544 of 17,006 (9%) currently in care.
  (In 2012: 1,530 (9%) of 16,169)

- Resistance tests available to SHM for only 25% of patients with virological failure.
  → True resistance prevalence estimated to be 40% (in line with other EU countries).
Topics

• **Epidemic trends over time**
  – New HIV diagnoses overall and by transmission risk group, gender, and age and stage of infection
  – Time of diagnosis: late vs. early

• **Quality of care**
  – The cascade of care in the Netherlands

• **Combination antiretroviral treatment outcomes**
  – Short- and long-term viro-/immunologic outcomes
  – Trends over time in tolerability of initial treatment
  – Virological failure and antiviral drug resistance

• **HIV in pregnancy, children and adolescents**

• **Mortality and morbidity**
  – AIDS vs. non-AIDS morbidity and mortality

• **Hepatitis B and C co-infection**

• **Conclusions**
Vertical transmission of HIV occurring within NL virtually nil
Overall MTCT risk reduced to <1%
HIV-infected children & adolescents

Long-term immunological recovery on cART

- Immediate treatment leads to better long-term immunological recovery
- 1/3 of children having transitioned to adult care and on cART had detectable HIV RNA at last known measurement (n=21/63)
- Challenge to maintain lifelong adherence to cART

Z-score of 0: Represents the age-appropriate median
Z-score of -1: Child’s CD4 count is 1 SD below the age-specific median of an HIV -ve reference population

Topics

- **Epidemic trends over time**
  - New HIV diagnoses overall and by transmission risk group, gender, and age and stage of infection
  - Time of diagnosis: late vs. early

- **Quality of care**
  - The cascade of care in the Netherlands

- **Combination antiretroviral treatment outcomes**
  - Short- and long-term viro-/immunologic outcomes
  - Trends over time in tolerability of initial treatment
  - Virological failure and antiviral drug resistance

- **HIV in pregnancy, children and adolescents**

- **Mortality and morbidity**
  - AIDS vs. non-AIDS morbidity and mortality

- Hepatitis B and C co-infection

- Conclusions
AIDS and death

- AIDS down significantly since cART, but still occurs
- Mortality overall still higher than in gender- and age-matched general population
- Mortality of patients successfully treated from an earlier stage of infection approaches that of general population
Causes of death

- AIDS remains major cause – 25% (late presentation)
- Shift to non-AIDS causes - NADM (malignancies) and cardiovascular
- Ageing population – more comorbidities
Increasing age of patients in care

- Median age of patients in care = 47 years
- 50 years or older
  - 1996: 9%
  - 2013: 37% (6% ≥65 years)
- Expected increase in age-related comorbidities
Multiple comorbidity and ageing

• AGEhIV study – number of comorbidities at time of enrolment
• Multiple comorbidities more prevalent in HIV-infected group, particularly in 65+
Comorbidities and ageing: HIV vs non-HIV

- **AGEhIV study** – prevalence of comorbidities at time of enrolment
- **Significantly more cardiovascular disease (CVD) and chronic kidney disease in HIV-infected group**
Comorbidities and ageing of patients in care in NL

Myocardial infarction, stroke, hypertension, diabetes mellitus, chronic kidney disease and non-AIDS-defining malignancies were assessed.

- Multiple co-morbidities more frequent with age
CVD risk of patients in care in NL

- Calculated using D:A:D study algorithm
- Over time, high risk % and very high risk % remained stable in spite of the population becoming older, suggesting better management of CVD risk
Topics

- **Epidemic trends over time**
  - New HIV diagnoses overall and by transmission risk group, gender, and age and stage of infection
  - Time of diagnosis: late vs. early

- **Quality of care**
  - The cascade of care in the Netherlands

- **Combination antiretroviral treatment outcomes**
  - Short- and long-term viro-/immunologic outcomes
  - Trends over time in tolerability of initial treatment
  - Virological failure and antiviral drug resistance

- **HIV in pregnancy, children and adolescents**

- **Mortality and morbidity**
  - AIDS vs. non-AIDS morbidity and mortality

- **Hepatitis B and C co-infection**

- Conclusions
HIV and viral hepatitis

- Annual prevalence of chronic HCV amongst HIV positives tested for HCV slowly decreased from 10% in 1999 to 5% in 2012
- Overall 5.3% of the tested population is diagnosed with chronic HCV

- Prevalence/year of chronic HBV amongst HIV positives decreased from 11% in 2000 to 8% in 2012
- Overall 9% of the tested population is diagnosed with chronic HBV
- Estimated 28% (21% for MSM) not exposed to HBV or vaccinated → increased HBV vaccine efforts necessary
HCV treatment uptake has increased with time
- Recent introduction of first-generation direct-acting antivirals
HCV treatment response to (peg)-IFN alfa + ribavirin

- Sustained virological response rates 41-56% for acute HCV and 14-42% for chronic HCV infection
Liver-related death in HIV and HBV/HCV co-infection

HBV
• Marked reduction since 2000 (due to tenofovir-containing cART)

HCV
• Some improvement since 2000
• With introduction of new DAA’s marked further reduction in liver-related morbidity and mortality expected

<table>
<thead>
<tr>
<th>Risk of liver-related death, hazard ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV</td>
</tr>
<tr>
<td>HIV/chronic HCV, &lt;2000</td>
</tr>
<tr>
<td>HIV/chronic HBV, &lt;2000</td>
</tr>
<tr>
<td>HIV/chronic HBV, &gt;2000</td>
</tr>
</tbody>
</table>
Topics

• **Epidemic trends over time**
  – New HIV diagnoses overall and by transmission risk group, gender, and age and stage of infection
  – Time of diagnosis: late vs. early

• **Quality of care**
  – The cascade of care in the Netherlands

• **Combination antiretroviral treatment outcomes**
  – Short- and long-term viro-/immunologic outcomes
  – Trends over time in tolerability of initial treatment
  – Virological failure and antiviral drug resistance

• **HIV in pregnancy, children and adolescents**

• **Mortality and morbidity**
  – AIDS vs. non-AIDS morbidity and mortality

• **Hepatitis B and C co-infection**

• **Conclusions**
Conclusions

Epidemic trends, quality of care and treatment outcomes

- The annual number of newly diagnosed patients linked to care remains stable, but notably shows no decline.
- Two thirds of new diagnoses are in MSM, particularly in both younger and older men.
- The rate of late presentation and entry into care remains unacceptably high, especially in heterosexual men and women.
- Approximately thirty percent of the total estimated number of PLWHIV in the Netherlands is not in care, most likely unaware of being infected, and importantly contributes to the continuous fuelling of the epidemic.
- The large majority of individuals linked to care is retained in care, receives cART and achieves sustained suppression of viraemia.
- This has resulted in the prevalence of antiretroviral drug resistance remaining relatively low and stable.
- The likelihood of achieving optimal long-term immune recovery is increased with earlier start of cART, both in adults and children.
Conclusions

Treatment outcomes, mortality and morbidity

• First-line regimens are increasingly maintained for longer, but toxicities remain the most frequent reason for regimen changes, illustrating the continued need for even better tolerated regimens

• The impact of cART on reducing overall mortality is sustained, but due to late presentation AIDS remains a frequent cause of death, and overall mortality higher than in the general population

• Causes of death in the increasingly aging population of PLWHIV have shifted towards non-AIDS causes, of which CVD and NADM are the most prominent

• Multiple simultaneous co-morbidities are more prevalent in older individuals with HIV on cART than in uninfected individuals

• Preliminary evidence suggests relatively successful management of CVD risk in the aging population of PLWHIV in the Netherlands
Conclusions

HIV and HVB/HCV co-infection

- There remains room for improving vaccination rates in persons at risk of acquiring hepatitis B infection.
- Increased use of tenofovir may have contributed to the observed decreased risk of dying from HBV-related liver disease in the last decade.
- In spite of increased uptake of treatment, HCV cure rates remain suboptimal.
- More effective and especially interferon-free regimens hold great promise for improving cure rates and reducing the future burden of chronic liver disease and liver-related mortality.
Future prospects

- Improved and earlier identification, linkage to care and treatment of persons living with HIV may be expected to:
  - Improve individual prognosis in terms of disease-free survival
  - Contribute to reducing the incidence of new HIV infections
Acknowledgements

Acknowledgements

**SHM**
Ard van Sighem  
Luuk Gras  
Colette Smit  
Anouk Kesselring  
Daniela Bezemer  
Esther Engelhard  
Sima Zaheri  
Louise Dolfing  
Michael van der Linde  
Danielle de Boer

**Clinical advisors**
Jan Prins  
Kees Brinkman  
Anne Wensing  
Ferdinand Wit  
Joop Arends  
Clemens Richter  
Anemarie van Rossum  
Liesbeth van Leeuwen

**CIb-RIVM**
Eline op de Coul
and all patients who allow us to collect and analyse data on the course and outcome of their infection